Mibolerone
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Mibolerone
|
|
| Systematic (IUPAC) name | |
| (7R,8R,9S,10R,13S,14S,17S)-17-hydroxy- 7,13,17-trimethyl-1,2,6,7,8,9,10,11,1
2,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C20H30O2 |
| Mol. mass | 302.4558 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | 2-4 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule 3 (US) |
| Routes | Oral |
Mibolerone is an Anabolic steroid which is very androgenic. It is about 5 times more potent than testosterone as an anabolic agent and about 2.5 times more potent as an androgenic agent. It is one of the most androgenic agents in existence and as an effect often causes progesterone related gynecomastia.
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
